Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
about
Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®)Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort.A retrospective analysis to identify predictors of COPD-related rehospitalization.Features of COPD patients by comparing CAT with mMRC: a retrospective, cross-sectional study.Significant pain variability in persons with, or at high risk of, knee osteoarthritis: preliminary investigation based on secondary analysis of cohort data"Frequent exacerbator" is a phenotype of poor prognosis in Japanese patients with chronic obstructive pulmonary disease.Impacts of coexisting bronchial asthma on severe exacerbations in mild-to-moderate COPD: results from a national database.Comorbidity as a contributor to frequent severe acute exacerbation in COPD patients.Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patientsDefining phenotypes in COPD: an aid to personalized healthcare.Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.The Relationship Between 24-Hour Symptoms and COPD Exacerbations and Healthcare Resource Use: Results from an Observational Study (ASSESS).Consistency of medical record reporting of a set of indicators for proactive palliative care in patients with chronic obstructive pulmonary disease.Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization.Determinants of exacerbation risk in patients with COPD in the TIOSPIR study.Evaluation of clinical variables according to follow-up times in COPD: results from ON-SINT cohort.Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources.'Exacerbation-free time' to assess the impact of exacerbations in patients with chronic obstructive pulmonary disease (COPD): a prospective observational study.Validation of ACCESS: an automated tool to support self-management of COPD exacerbations
P2860
Q35350962-B482FFF9-0CF9-4BC0-A004-AFE33452BCB8Q35804617-8E6925C0-0EE3-4274-B294-11A7E061B21CQ35919103-963F28A6-D17D-416C-B257-3B37F51B6C4EQ36004028-8DB6B45C-94B4-4157-9A88-801651DAABB3Q36250075-03E93A0C-AAA1-43F4-8CE6-AC377BB86A00Q36280384-FD5E24CE-85C4-49B8-9698-F3341E00050DQ36557724-9A063068-CB6D-44A6-899C-087B2EEC2366Q36826833-EEB35784-53EF-447A-BE46-96796A1DD233Q37158368-6A8574F3-CCA9-438D-8520-61C76FEFDB16Q37242230-DE9C70D1-F8F8-46F9-ACEF-FA8395979927Q38208244-900CBEA1-8BBF-4E8A-9E36-527FFF0BBD77Q38751226-494DD1B4-F349-43DF-B9EC-8F19986396BDQ38894424-51565C23-F1AE-4153-8AF9-4D013E92CE7DQ39016048-73550C25-8330-4D19-A1DD-46BC8229A937Q41020098-F1CB4504-99FD-4B37-B6C1-62D6C7695057Q47108348-A56A60F2-145C-4E38-A68E-E7BC929AB890Q47131947-A0C5AE05-2639-4BE7-B4F9-344D554AC568Q47139198-B6CCF59A-D86F-4468-9733-EA64D3CB470CQ55007112-DA92C93F-7B02-4D52-BBEC-FDAFB72A28BDQ57816225-603D8BB3-8F0A-416F-84F2-1DE930D89EBB
P2860
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
@en
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
@nl
type
label
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
@en
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
@nl
prefLabel
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
@en
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
@nl
P2093
P2860
P356
P1433
P1476
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial
@en
P2093
Claus F Vogelmeier
Hendrik Schmidt
Kai M Beeh
Klaus F Rabe
Susanne Stowasser
Thomas Glaab
P2860
P2888
P356
10.1186/1465-9921-14-116
P577
2013-10-29T00:00:00Z
P5875
P6179
1003625655